Log in

NASDAQ:BLPH - Bellerophon Therapeutics Stock Price, Forecast & News

$12.30
-0.37 (-2.92 %)
(As of 03/31/2020 02:24 AM ET)
Today's Range
$11.61
Now: $12.30
$21.00
50-Day Range
$0.28
MA: $7.64
$18.00
52-Week Range
$3.19
Now: $12.30
$26.00
Volume5.26 million shs
Average Volume856,232 shs
Market Capitalization$56.36 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.53
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.
Read More
Bellerophon Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLPH
CUSIPN/A
Phone908-574-4770

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$0.67 per share
Book Value$0.84 per share

Profitability

Net Income$2.81 million

Miscellaneous

Employees17
Market Cap$56.36 million
Next Earnings Date4/2/2020 (Estimated)
OptionableNot Optionable

Receive BLPH News and Ratings via Email

Sign-up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.


Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

How has Bellerophon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLPH shares have increased by 95.5% and is now trading at $12.30. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bellerophon Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellerophon Therapeutics.

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 2nd 2020. View our earnings forecast for Bellerophon Therapeutics.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics Inc (NASDAQ:BLPH) posted its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.20. View Bellerophon Therapeutics' earnings history.

When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work?

Bellerophon Therapeutics's stock reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for BLPH?

2 equities research analysts have issued 1 year target prices for Bellerophon Therapeutics' shares. Their forecasts range from $30.00 to $30.00. On average, they expect Bellerophon Therapeutics' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 143.9% from the stock's current price. View analysts' price targets for Bellerophon Therapeutics.

What are Wall Street analysts saying about Bellerophon Therapeutics stock?

Here are some recent quotes from research analysts about Bellerophon Therapeutics stock:
  • 1. Maxim Group analysts commented, "Bellerophon reported 2Q19 with a net loss of ($4.1M) and $16.8M in cash on the balance sheet. At the current burn rate of ~$4M-$5M per quarter, the company should be funded through 1H20 and importantly through the next infection point; Cohort-2 data in PH-ILD expected by YE19." (8/9/2019)
  • 2. According to Zacks Investment Research, "Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. " (5/15/2019)

Has Bellerophon Therapeutics been receiving favorable news coverage?

News headlines about BLPH stock have trended very negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bellerophon Therapeutics earned a media sentiment score of -3.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutBellerophon Therapeutics.

Are investors shorting Bellerophon Therapeutics?

Bellerophon Therapeutics saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 50,300 shares, a drop of 46.9% from the February 27th total of 94,800 shares. Based on an average trading volume of 57,700 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.5% of the company's shares are sold short. View Bellerophon Therapeutics' Current Options Chain.

Who are some of Bellerophon Therapeutics' key competitors?

What other stocks do shareholders of Bellerophon Therapeutics own?

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the following people:
  • Fabian Tenenbaum, Chief Executive Officer & Director
  • Assaf Korner, Chief Financial Officer & Secretary
  • Amy Edmonds, VP-Clinical Operations & Administration
  • Martin Dekker, Vice President-Engineering & Manufacturing
  • Peter Fernandes, Chief Regulatory & Safety Officer

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $12.30.

How big of a company is Bellerophon Therapeutics?

Bellerophon Therapeutics has a market capitalization of $56.36 million. The biotechnology company earns $2.81 million in net income (profit) each year or ($5.10) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe. View additional information about Bellerophon Therapeutics.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is http://www.bellerophon.com/.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]


MarketBeat Community Rating for Bellerophon Therapeutics (NASDAQ BLPH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  300 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  505
MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe BLPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel